文献速递胸部肿瘤

免疫组化评估的PD-L1蛋白表达在已切除的非小细胞肺癌中既非预后因素也不能预测辅助化疗获益

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该汇总分析对三项辅助化疗试验(IALT、JBR.10、CALGB 9633)的982例肿瘤切片用E1L3N抗体行PD-L1免疫组化,由两名病理学家评分肿瘤细胞和免疫细胞的染色强度与百分比。结果显示PD-L1表达与鳞状组织学、密集淋巴细胞浸润和KRAS相关,与TP53突变无关;在≥1%、≥10%、≥25%界值下均既非预后因素,也不能预测辅助化疗的生存获益。

要点

  • 982例可分析,肿瘤细胞PD-L1阳性率在≥1%、≥10%、≥25%界值下分别为32.0%、20.8%、14.3%。
  • 免疫细胞PD-L1阳性率在≥1%、≥10%、25%界值下分别为38.7%、31.4%、15.1%。
  • PD-L1阳性与鳞状组织学、密集淋巴细胞浸润和KRAS相关,与TP53突变无关。

核心结论

  • PD-L1免疫组化在早期非小细胞肺癌患者中不是预后因素。
  • PD-L1免疫组化也不能预测这些患者从辅助化疗中获益。

研究设计与样本

  • 汇总分析纳入三项辅助化疗试验(IALT、JBR.10、CALGB 9633)的肿瘤切片,用E1L3N抗体行PD-L1免疫组化。
  • 由两名病理学家对肿瘤细胞和免疫细胞的PD-L1染色强度与百分比评分,共982例患者可分析。

主要发现

  • 肿瘤细胞PD-L1阳性(任意强度)在≥1%、≥10%、≥25%界值下分别为314例(32.0%)、204例(20.8%)、141例(14.3%)。
  • 免疫细胞PD-L1阳性在≥1%、≥10%、25%界值下分别为380例(38.7%)、308例(31.4%)、148例(15.1%)。
  • PD-L1阳性与鳞状组织学、密集淋巴细胞浸润和KRAS相关,与TP53突变无关。
  • EGFR突变肿瘤显示PD-L1表达较低,但未达统计学显著。
  • PD-L1表达在这些界值及其他探索性界值下均既非预后因素,也不能预测辅助化疗的生存获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The expression of programmed death (PD) ligand 1 (PD-L1) protein expression assessed by immunohistochemistry (IHC) has been correlated with response and survival benefit from anti-PD-1/PD-L1 immune checkpoint inhibitor therapies in advanced non-small cell lung carcinoma (NSCLC). The efficacy of several agents appears correlated with PD-L1 expression. It remains controversial whether PD-L1 is prognostic in NSCLC. We assessed the prognostic value of PD-L1 IHC and its predictive role for adjuvant chemotherapy in early stage NSCLC. PATIENTS AND METHODS: Tumor sections from three pivotal adjuvant chemotherapy trials (IALT, JBR.10, CALGB 9633) using the E1L3N antibody were studied in this pooled analysis. PD-L1 staining intensity and percentage in both tumor cells (TCs) and immune cells (ICs) were scored by two pathologists. The average or consensus PD-L1 expression levels across intensities and/or percent cells stained were correlated with clinicopathological and molecular features, patient survivals and potential benefit of adjuvant chemotherapy. RESULTS: Results from 982 patients were available for analysis. Considering staining at any intensities for overall PD-L1 expression, 314 (32.0%), 204 (20.8%) and 141 (14.3%) tumor samples were positive for PD-L1 staining on TCs using cut-offs at ≥1%, ≥10% and ≥25%, respectively. For PD-L1 expressing ICs, 380 (38.7%), 308 (31.4%) and 148 (15.1%) were positive at ≥ 1%, ≥10% and 25% cut-offs, respectively. Positive PD-L1 was correlated with squamous histology, intense lymphocytic infiltrate, and KRAS but not with TP53 mutation. EGFR mutated tumors showed statistically non-significant lower PD-L1 expression. PD-L1 expression was neither prognostic with these cut-offs nor other exploratory cut-offs, nor were predictive for survival benefit from adjuvant chemotherapy. CONCLUSIONS: PD-L1 IHC is not a prognostic factor in early stage NSCLC patients. It is also not predictive for adjuvant chemotherapy benefit in these patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Tsao MS, Le Teuff G, Shepherd FA, et al. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol. 2017. PMID: 28137741. doi:10.1093/annonc/mdx003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。